From professional translators, enterprises, web pages and freely available translation repositories.
disse symptomer var ledsaget af hypotension og bronchospasme i omkring 10% af tilfældene.
these symptoms were accompanied by hypotension and bronchospasm in about 10% of the cases.
-patienter med astma bronkiale.hos disse patienter er det især risikoen for bronchospasme, der er
-patients with bronchial asthma; in these patients it is especially the risk of bronchospasm which is
generelt kan senreaktioner, såsom kontaktdermatitis, forekomme, men akutte reaktioner med bronchospasme forekommer sjældent.
generally, delayed type reactions such as contact dermatitis may occur, but rarely immediate reactions with bronchospasm may occur.
meget sjældne:hoste rhinitis bronchospasme, sinusitis..allergisk alveolitis/eosinofil pneumoni.
cough rhinitis bronchospasm, sinusitis, allergic alveolitis/eosinophilic pneumonia
hos patienter, som udvikler tegn på alvorlige reaktioner, især alvorlig dyspnø, bronchospasme eller hypoxi, skal infusionen straks afbrydes.
patients who develop evidence of severe reactions, especially severe dyspnoea, bronchospasm or hypoxia should have the infusion interrupted immediately.
yderligere reaktioner omfatter kvalme, urtikaria, opkastning, træthed, dyspnø, hovedpine, pruritus, diarré og bronchospasme.
additional reactions include nausea, urticaria, vomiting, fatigue, dyspnoea, headache, pruritus, diarrhoea and bronchospasm.
alvorligt cytokin frigivelsessyndrom er karakteriseret ved alvorlig dyspnø ofte sammen med bronchospasme og hypoxi, foruden feber, kulderystelser, rigor, urticaria og angioødem.
severe cytokine release syndrome is characterised by severe dyspnea, often accompanied by bronchospasm and hypoxia, in addition to fever, chills, rigors, urticaria, and angioedema.
meget sjældne (i mindre end 1 ud af 10. 000 patienter) , åndedrætsproblemer (bronchospasme) er blevet rapporteret.
very rarely (less than 1 in 10,000 patients) , difficulty breathing (bronchospasm) has been reported.
denne undervisningspakke har til hensigt at øge bevidstheden om den potentielle risiko for hypotension, bradykardi og bronchospasme efter indtagelse af hemangiol og give vejledning om, hvordan denne risiko skal monitereres/håndteres.
this educational pack is aimed at increasing awareness about the potential risk of hypotension, bradycardia, and bronchospasm, after taking hemangiol, and providing guidance on how to monitor/manage that risk.
infusionsrelaterede bivirkninger herunder cytokin frigivelsessyndrom (se pkt.4. 8) ledsaget af hypotension og bronchospasme er set hos 10% af patienter behandlet med mabthera.
infusion related adverse reactions including cytokine release syndrome (see section 4.8) accompanied by hypotension and bronchospasm have been observed in 10% of patients treated with mabthera.
angående infektion i de nedre luftveje, så som bronkitis eller bronchiolitis, blev der observeret en forværring af symptomerne (inklusive bronchospasme) hos patienter behandlet med hemangiol på grund af propranolols bronchokonstriktive effekter.
concerning the lower respiratory tract infections like bronchitis or bronchiolitis, an aggravation of symptoms (including bronchospasm) has been observed in patients treated with hemangiol due to the bronchoconstrictive effect of propranolol.
mulige histamin- medierede symptomer er blevet rapporteret inkluderende tilfælde af udslæt, hævelse af ansigtet, pruritus, varmefølelse eller bronchospasmer.
possible histamine-mediated symptoms have been reported including reports of rash, facial swelling, pruritus, sensation of warmth, or bronchospasm.